PTPRC and hematoma: Similarly, TO901317 treatment significantly reduced the number of CD45-positive cells in the peri-hematoma area at 4 days (22.6 ± 1.7 cells/field versus 30.6 ± 0.5 cells/field, P = 0.0043; Fig. 6c) and 7 days (21.5 ± 1.0 cells/field versus 25.7 ± 1.3 cells/field, P = 0.0256) compared with the control group.